Alkem Laboratories Limited
Alkem Laboratories Limited is a Public Non-govt company company incorporated in 1973 and based in Maharashtra, India. Alkem Laboratories Limited operates in Other (NIC 00305) with authorized capital of ₹50.00 Cr and paid-up capital of ₹23.91 Cr. For 2025-26, the company reported revenue of ₹14712.00 Cr and profit after tax of ₹2351.00 Cr. The board has 2 active directors. RegisterKaro's provisional Compliance Health Score for the company is 67/100 (grade C), based on 4 of 9 signals — full scoring is pending extraction of the company's MCA filing history.
Alkem Laboratories Limited is the legal entity of Alkem Laboratories, Connect2Clinic, Enzene Biosciences and Cachet Pharma.
Quick facts
Directors
2 activeMCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | 0d | filed |
| MGT-7 | FY2024-25 | 26 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | 0d | filed |
| MGT-7 | FY2023-24 | 27 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 26 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Alkem Laboratories Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 314828100 | HDFC Bank Ltd(Bank) | ₹23.02 Cr | 27 Jan 2020 | Satisfied |
| 147743188 | Axis Bank Ltd(Bank) | ₹12.10 Cr | 04 Jul 2019 | Open |
| 359577785 | State Bank of India(Bank) | ₹22.83 Cr | 04 Jul 2023 | Satisfied |
| 363901843 | Kotak Mahindra Bank Ltd(Bank) | ₹8.34 Cr | 27 Jan 2021 | Open |
| 293674491 | Kotak Mahindra Bank Ltd(Bank) | ₹1.16 Cr | 19 Sep 2023 | Satisfied |
Charge IDs, lenders & amounts for Alkem Laboratories Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2025-26 | — | ||||
| 2024-25 | — | ||||
| 2023-24 | — |
Detailed Financials
3 FYs| Line item | 2025-26 | 2024-25 | 2023-24 |
|---|---|---|---|
| Income statement | |||
| Revenue from operations | |||
| Other income | |||
| Total income | |||
| Total expenses | |||
| Profit before tax | |||
| Profit / (Loss) after tax | |||
| Balance sheet | |||
| Equity / Net worth | |||
| Borrowings | |||
| Current liabilities | |||
| Total liabilities | |||
| Current assets | |||
| Cash & equivalents | |||
| Total assets | |||
| Employees | — | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2025-26 | +27.0% | — | — | |
| Profit after Tax2025-26 | +7.0% | — | — | |
| Net Worth2025-26 | +19.0% | — | — |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2023-24 | +14.30% | — | +17.56% | +11.63% | — | |||
| 2024-25 | +17.08% | +2.34% | +18.48% | +12.52% | — | |||
| 2025-26 | +15.98% | +13.47% | +17.01% | +11.26% | — |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 3 | 2,44,41,370 | 83.65% |
| Institutional Investors | 3 | 6,56,296 | 2.25% |
| Public & Others | 18 | 41,19,585 | 14.10% |
Promoter, institutional & public holding for Alkem Laboratories Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
9 peersEvents & timeline
3External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.